Since their introduction almost 50 years ago as one of the first orally effective antihypertensive agents, diuretics have maintained their place as one of the most commonly used agents for the treatment of hypertension. Their use has been proportionally higher in the US, where they are recommended for the initial choice of therapy for most patients, 1 than they are in Europe, where they are included as one of multiple preferred choices for initial therapy. 2 
The importance of low doses
There are many rationales behind the common use of diuretics that will be described. However, one point needs emphasis before all else: only low doses of diuretic have been found to provide the full protection against cardiovascular events that would be anticipated from their antihypertensive efficacy. Doses equivalent to 12.5 up to 25 mg of hydrochlorothiazide (HCTZ) (which is well met by indapamide 1.5 mg, sustained release) clearly are as effective as any of the other major classes of drugs. 3 However, larger doses, equivalent to 50 mg or more of HCTZ, have not been found to provide the degree of cardiovascular protection that would be expected from their antihypertensive effect. 4 There are multiple reasons why high doses may be counterproductive. Of these, the activation of counter-regulatory mechanisms is more prominent. High doses that induce significant volume depletion and immediate falls in blood pressure activate the reninangiotensin-aldosterone mechanism and turn on the sympathetic nervous system. 5 Thereby, more potassium wastage and hypokalaemia develop and, likely as a consequence of vasoconstriction of peripheral blood flow through tissues wherein insulin effects are manifest, insulin resistance develops. Perhaps as a consequence of volume contraction and haemoconcentration, blood lipid levels increase and prothrombotic mechanisms may be activated.
Regardless of why high doses do not protect, the clinical evidence is clear: only relatively low doses of diuretics reduce cardiovascular events.
The evidence from randomized controlled trials and cardiovascular mortality compared to placebo and to be virtually equal in protection to therapy based on other classes of drugs ( Figure 1 ). In this meta-analysis, all published randomized controlled trails (RCTs) from 1967 to early 2003 were examined, combining data from 42 trials that included over 190 000 patients. 3 In the Blood Pressure Lowering Treatment Trialists Collaboration, only those RCTs published since 1995 were included, including data from 29 trials covering over 160 000 patients. Since the RCTs comparing diuretics with placebo were all published before 1995, the Trialists' meta-analysis did not portray the evidence that diuretics were superior to placebo.
The Trialists' analysis of the trials comparing diuretics with calcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEIs) included trials in which beta-blockers were often included with the diuretic arm. In truth, none of the trials were 'pure', with few of the participants randomized to one drug kept only on that one drug throughout the trial. In order to achieve the predetermined goal of the therapy, a mixture of other drugs has been universal, in some trials reaching the majority of patients, although few subjects received the comparator drug. That is, if the trial compared a diuretic vs a CCB, those in either group might receive a beta-blocker or ACEI but those in the diuretic arm would not be given a CCB, nor would those in the CCB arm be given a diuretic.
A good example of the problem is the massive Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 7 The patients were randomly allocated to one of four classes-a diuretic, an alpha-blocker, an ACEI, or a CCB. In order to achieve the goal of a blood pressure below Figure 1 Meta-analysis of first-line treatment strategies in RCTs in hypertension. CHD indicates coronary heart disease; CHF, congestive heart failure; CI, confidence interval; CVD, cardiovascular disease; and RR, relative risk (modified from Psaty BM et al).
140/90 mmHg, 65% of the enrollees ended up on two or more drugs, although few were given one of the other comparator classes. Thus, all of the data such as portrayed in both of the recent metaanalyses 3,6 must be recognized as evidence of the value of therapy that is based on one or another drug but not purely derived from the effect of a single agent.
In recognition of the usual need for additional drugs beyond monotherapy in order to achieve the appropriate goals of therapy-below 140/90 mmHg in uncomplicated hypertension, below 130/80 mmHg in those with diabetes, renal or cardiac disease-current guidelines advocate the initiation of therapy with combinations of two drugs in those patients with higher levels of blood pressure or overall cardiovascular risk.
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Enhancement of benefit of other drugs
In keeping with this recommendation to often start with a combination of two drugs for many patients, there is strong rationale for including a low-dose diuretic as one of these two components. The efficacy of all other classes of antihypertensive drugs is enhanced by the presence of a diuretic. On a theoretical level, the enhancement is based on prevention of the reactive renal sodium retention that is invoked whenever the blood pressure is lowered (Figure 2) . On a clinical basis, multiple trials have clearly documented both the additive antihypertensive efficacy and the better protection against target organ damages by the addition of a low dose of diuretic, perhaps most strikingly in the Perindopril Protection against Recurrent Stroke Study (PROGRESS) trial of indapamide added to the ACEI perindopril. 8 
Benefits beyond blood pressure reduction
Low doses of diuretic have also been shown to increase calcium reabsorption in the renal tubule, thereby reducing excretion of calcium and, as a consequence, reducing the formation of calciumcontaining kidney stones. 9 At the same time, it reduces the reabsorption of calcium from bone and, as a consequence, reduces the rate of osteoporosis and bone fractures in the elderly. 10 Favourable side-effect profile Low doses of diuretic largely avoid the side effects sometimes seen with higher doses. These include hypokalaemia from renal potassium wastage, insulin resistance inducing glucose intolerance and diabetes, and rises in serum cholesterol. There remains a potential for adverse metabolic effects so that occasional monitoring of serum potassium and glucose are recommended even with low doses.
The rise in serum uric acid that reflects the increase in renal tubular reabsorption of urate, in concert with sodium and calcium, is also mitigated with lower doses but some elevation is to be expected.
This favourable side-effect profile has been demonstrated with indapamide 1.5 mg, sustained release, where lipid and carbohydrate profiles remain stable over the long term.
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Some have taken the biochemical aberrations noted in the ALLHAT population whose therapy was based on the diuretic chlorthalidone to question the safety of diuretics. There was a higher percentage of both hypokalaemia and hyperglycaemia in those on the diuretic-based regimen than on the ACEI-or CCB-based regimens. 7 However, chlorthalidone is considerably more potent and longer lasting than HCTZ 12 and most of the patients who were started on 12.5 mg ended up on 25 mg a day. This 25 mg of chlorthalidone is likely equivalent to 40 mg of HCTZ, certainly not a low dose. Therefore, although long-term surveillance of possible side effects of even low doses is appropriate, the prolonged use of low-dose diuretic has not been associated with an increased incidence of diabetes. 13 In the desire to avoid all possible side effects of long-acting diuretics, some practitioners have turned to the use of short-acting loop diuretics, in particular furosemide. Whereas multiple daily doses of furosemide may maintain the slight shrinkage of circulating blood volume that is the primary mechanism of the antihypertensive effect of diuretics, once-a-day furosemide will not. Although oncea-day furosemide may provide a useful diuresis in chronically oedematous patients, in particular those with congestive heart failure, it will not serve as an effective antihypertensive.
The use of currently provided low doses of diuretic, that is, 12.5 to 25 mg of HCTZ or 1.5 mg of indapamide, 14 sustained release, strikes the correct balance: enough drug to achieve a slight shrinkage of blood volume, not so much drug as would threaten the integrity of cardiovascular homeostasis.
Systolic blood pressure and cardiovascular events
Systolic blood pressure (SBP) is a better predictor of cardiovascular events (coronary heart disease, heart failure, stroke, and all-cause mortality) than diastolic blood pressure (DBP), especially among elderly people. 15 Furthermore, SBP is more difficult to decrease than DBP. Randomized controlled outcome trials of antihypertensive treatment reported much greater success in decreasing DBP than SBP (90 vs 60% control rates). Among all antihypertensive therapeutic classes, low-dose diuretics have been proven to decrease SBP. Thus, low-dose diuretics are recommended for the initial choice of antihypertensive therapy in the 7th US Joint National Committee report and the control of systolic hypertension deserves particular emphasis in daily practice, especially in elderly patients.
Conclusion
After almost 50 years of extensive use for the treatment of hypertension, diuretics have proved to be both effective and safe. As noted by Psaty et al 3 in their comments on the meta-analysis of all currently available outcome data: 'Low-dose diuretics are the most effective first-line treatment for preventing the occurrence of cardiovascular disease morbidity and mortality.'
